📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
NEUTRAL
score: 0.33
SENTIMENT
NEUTRAL
TOTAL VIEWS
13
ORIC Stock Analysis & AI Grade: NEUTRAL
3 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 3 ARTICLES
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals disclosed routine equity grants totaling 125,400 non-qualified stock options and 20,550 restricted stock units...
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC)
ORIC Pharmaceuticals has progressed rinzimetostat into a global Phase 3 trial (Himalayas-1) targeting metastatic castration-resistant...
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC Pharmaceuticals announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, with...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice